$IXHL News

Last published 2mo ago

2mo agoIXHLIncannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital PositionGlobeNewswirePatient dosing commenced in the DReAMzz Phase 2 dose-optimization study of IHL-42X in obstructive sleep apneaU.S. composition and methods of treatment patent granted covering IHL-42X with baseline expiry in
2mo agoIXHLIncannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42XGlobeNewswireNEW YORK and MELBOURNE, Australia, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing
3mo agoIXHLIncannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026GlobeNewswireNEW YORK and MELBOURNE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing
3mo agoIXHLIncannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep ApneaGlobeNewswireFirst clinical sites approved and actively screening potential participantsRepresents another major milestone in the advancement of IHL-42X towards Phase III developmentIHL-42X has received FDA Fast Track designation,
4mo agoIXHLIncannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep ApneaGlobeNewswireMELBOURNE, Australia and NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing
5mo agoIXHLIncannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial FlexibilityGlobeNewswireNEW YORK and MELBOURNE, Australia, June 10, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing innovative combination
5mo agoIXHLIncannex Announces Initiation of Research Coverage by Alliance Global PartnersGlobeNewswireMELBOURNE, Australia and NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing innovative combination
6mo agoIXHLIncannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep ApneaGlobeNewswireMELBOURNE, Australia and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company advancing innovative combination therapies for high-impact
6mo agoIXHLIncannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug DevelopmentGlobeNewswireMELBOURNE, Australia and NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company advancing innovative combination therapies for high-impact
6mo agoIXHLIncannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech BreakthroughGlobeNewswireLOS ANGELES, May 07, 2026 (GLOBE NEWSWIRE) -- MedTech Breakthrough, an independent market intelligence organization that recognizes the most innovative companies, technologies and products in the global digital health
6mo agoIXHLIncannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental IllnessGlobeNewswireMELBOURNE, Australia and NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today supports the
7mo agoIXHLIncannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic PositionGlobeNewswireMELBOURNE, Australia and NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced that
7mo agoIXHLIncannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea ResearchGlobeNewswireMELBOURNE, Australia and NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications,
8mo agoIXHL IHXLIncannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireNEW YORK and MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IHXL), ("Incannex" or the "Company") a clinical-stage biopharmaceutical company leading the way in
8mo agoIXHLIncannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 OutcomesGlobeNewswireMELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced an
8mo agoIXHLIncannex Announces Reverse Stock SplitGlobeNewswireMELBOURNE, Australia and NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage pharmaceutical company developing innovative combination
9mo agoIXHLIncannex Healthcare Announces Additional Appointments to Clinical Advisory BoardGlobeNewswireMELBOURNE, Australia and NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced the
9mo agoIXHLIncannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 ProgramGlobeNewswireMELBOURNE, Australia and NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, announces the
10mo agoIXHLIncannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence AwardsGlobeNewswireMELBOURNE, Australia and NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced that
10mo agoIXHLIncannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026GlobeNewswireMELBOURNE, Australia and NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, provides a 2025
11mo agoIXHLIncannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)GlobeNewswireMELBOURNE, Australia and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, announces that the
1y agoIXHLIncannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic FocusGlobeNewswireMELBOURNE, Australia and NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL)("Incannex" or the "Company"), a clinical-stage pharmaceutical company developing innovative combination
1y agoIXHLIncannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RequirementGlobeNewswireMELBOURNE, Australia and NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact medical
1y agoIXHLIncannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety DisorderGlobeNewswireMELBOURNE, Australia and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company") is pleased to report positive data from its Phase 2 clinical trial of PSX-001
1y agoIXHLIncannex Healthcare Authorizes $20 Million Share Repurchase ProgramGlobeNewswireMELBOURNE, Australia and NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative combination
1y agoIXHLIncannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep ApnoeaGlobeNewswireMELBOURNE, Australia and NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage pharmaceutical company developing innovative combination therapies for prevalent medical
1y agoIXHLIncannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near TermGlobeNewswireMELBOURNE, Australia, July 31, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company") announced, in response to recent questions it received from a number of its stockholders,
1y agoIXHLIncannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42XGlobeNewswireStatistically and clinically significant improvements across key clinical endpoints; IHL-42X reduced AHI by up to 83% from baseline. IHL-42X demonstrates compelling clinical benefit and an outstanding safety profile that
1y agoIXHLIncannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. GamaldoGlobeNewswireNEW YORK and MELBOURNE, Australia, July 25, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing combination drug therapies
1y agoIXHLIncannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. KirschGlobeNewswireNEW YORK and MELBOURNE, Australia, June 24, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing combination drug therapies
1y agoIXHLIncannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42XGlobeNewswireNEW YORK and MELBOURNE, Australia, June 18, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing combination drug therapies
1y agoIXHLIncannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted TherapyGlobeNewswireNEW YORK and MELBOURNE, Australia, June 17, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing combination drug therapies
1y agoIXHLIncannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM ExecutionGlobeNewswireNEW YORK and MELBOURNE, Australia, June 12, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing combination drug therapies
1y agoIXHLIncannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) ProgramGlobeNewswireNEW YORK and MELBOURNE, Australia, June 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company leading the way in developing oral
1y agoIXHLIncannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol ClearanceGlobeNewswireNEW YORK and MELBOURNE, Australia, May 29, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage pharmaceutical company developing novel combination therapies, today announced that the Phase
1y agoIXHLIncannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline ResultsGlobeNewswireMELBOURNE, Australia and NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications,
1y agoIXHLIncannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential DilutionGlobeNewswireNEW YORK and MELBOURNE, Australia, May 20, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company pioneering the development of
1y agoIXHLIncannex Announces Potential Reduction of Up to 50.4% of its Series A WarrantsGlobeNewswireNEW YORK and MELBOURNE, Australia, May 16, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), ("Incannex"), a clinical-stage biopharmaceutical company leading the way in developing oral combination
1y agoIXHLIncannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business UpdatesGlobeNewswireNEW YORK and MELBOURNE, Australia, May 15, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination
1y agoIXHLIncannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)GlobeNewswirePatient dosing completed in Phase 2 portion of Phase 2/3 RePOSA study evaluating IHL-42X oral treatment for OSA.End-of-study follow-up assessments on track for completion by May 17, 2025.Topline results expected in July
1y agoIXHLIncannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)GlobeNewswireNEW YORK and MELBOURNE, Australia, April 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing new oral combination
1y agoIXHLIncannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq RulesGlobeNewswireNEW YORK and MELBOURNE, Australia, March 07, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination
1y agoIXHLIncannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business UpdatesGlobeNewswirePositive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Application (NDA) submissionNew OSA Clinical Advisory Board Announced; Appoints Dr. Alison Wimms,
1y agoIXHL RMDIncannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory BoardGlobeNewswireNEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines
1y agoIXHLIncannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep ApneaGlobeNewswireDemonstrated bioavailability of IHL-42X, Incannex's proprietary combination formulation, confirming delivery of both dronabinol and acetazolamideAchieved similar PK and equivalent total drug exposure levels of IHL-42X
1y agoIXHLIncannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business UpdatesGlobeNewswireNEW YORK and MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with
2y agoIXHLIncannex Announces Appointment of Dr. Lou Barbato as Chief Medical OfficerGlobeNewswireNEW YORK and MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with
2y agoIXHLIncannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business UpdatesGlobeNewswireAnnounced strategic financing with Arena Investors, providing access to up to $59.0 million USD in gross proceeds to Incannex Announced positive top-line results from our Phase 2 proof-of-concept clinical trial of
2y agoIXHLIncannex Healthcare Announces Strategic Financing for up to $60 Million with Arena InvestorsGlobeNewswireNEW YORK and MELBOURNE, Australia, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (the "Company" or "Incannex"), a clinical-stage biopharmaceutical company developing life-changing medicines
2y agoIXHLFDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to ProceedGlobeNewswireApproval from FDA to proceed with 94 patient Phase 2 clinical trial received following review of IND dossier containing information on the clinical trial, as well as safety and quality of the investigational drug